natgillin/translations-raw huggingface dataset:
Grade 3 or 4 reactions occurred in 1.3 % of patients who received Pom + LD-Dex, and no patients who received HD-Dex.
Reakcije 3. ali 4. stopnje so se pojavile pri 1,3 % bolnikov, ki so prejemali Pom + NO-deks, in pri nobenem od bolnikov, ki so prejemali VO-deks.
Grade 3 or 4 thrombocytopenia and neutropenia occurred in 19% and 17% respectively, of patients treated for malignant glioma.
Trombocitopenija in nevtropenija stopnje 3 ali 4 sta se pojavili pri 19 % oziroma 17 % bolnikov, ki so se zdravili zaradi malignega glioma.
Grade 3 or 4, or recurrent Grade 2
3. ali 4. stopnja ali ponovni pnevmonitis 2. stopnje
Grade 3 or Grade 4 thrombocyte abnormalities, including thrombocytopenic events were observed in 14 % of the patients who received TMZ.
Anomalije trombocitov 3. ali 4. stopnje, vključno s trombocitopeničnimi sopojavi, so opažali pri 14 % bolnikov, ki so prejeli zdravilo TMZ.
Grade 3 or Grade 4 thrombocyte abnormalities, including thrombocytopenic events were observed in 14% of the patients who received TMZ.
Nepravilnosti trombocitov stopnje 3 ali 4, vključno s trombocitopeničnimi dogodki, so opazili pri 14 % bolnikov, ki so se zdravili s TMZ.
Grade 3 or Grade 4 thrombocyte abnormalities, including thrombocytopenic reactions were observed in 14% of the patients who received TMZ.
Anomalije trombocitov stopnje 3 ali 4, vključno s trombocitopeničnimi dogodki, so bile opažene pri 14 % bolnikov, ki so prejemali TMZ.
Grade 3 or higher
Stopnja 3 ali višja stopnja
Grade 3 or higher adverse reaction
Neželeni učinek 3. ali višje stopnje
Grade 3 or higher anaemia occurred in 10.3% of patients treated with ONIVYDE+5-FU/LV and in 6.7% of patients treated with 5-FU/LV.
Anemija 3. ali višje stopnje se je pojavila pri 10,3 % bolnikov, zdravljenih z zdravilom ONIVYDE+5-FU/LV, in pri 6,7 % bolnikov, zdravljenih s 5-FU/LV.
Grade 3 or higher neutropenia occurred more frequently in patients treated with ONIVYDE+5-FU/LV (27.4%) compared to patients treated with 5-FU/LV (1.5%).
Nevtropenija 3. ali višje stopnje je bila pogostejša pri bolnikih, zdravljenih z zdravilom ONIVYDE+5-FU/LV (27,4 %), v primerjavi z bolniki, zdravljenimi s 5-FU/LV (1,5 %).
Grade 3 or higher of febrile neutropenia was 37.9%.
Febrilne nevtropenije 3. stopnje ali višje je bilo 37,9 %.
Grade 3 or higher pneumonia occurred more frequently among elderly patients treated with IMBRUVICA (13% of patients age ≥ 65 versus 7% of patients < 65 years of age).
Pri starejših bolnikih, ki so prejemali zdravilo IMBRUVICA, se je pogosteje pojavila pljučnica stopnje 3 ali več (13% bolnikov, starih ≥ 65 v primerjavi s 7% bolnikov < 65 let).
Grade 3 or higher thrombocytopenia occurred in 2.6% of patients treated with ONIVYDE+5-FU/LV and 0% in patients treated with 5-FU/LV.
Trombocitopenija 3. ali višje stopnje se je pojavila pri 2,6 % bolnikov, zdravljenih z zdravilom ONIVYDE+5-FU/LV, in pri 0 % bolnikov, zdravljenih s 5-FU/LV.
Grade 3 or higherc
Stopnja 3 ali višja stopnjac
Grade 3 proteinuria was reported in up to 8.1% of treated patients.
O proteinuriji stopnje 3 so poročali pri največ 8,1 % zdravljenih bolnikov.
Grade 3 QTc prolongation
podaljšanje intervala QTc stopnje 3
Grade 3 rash Withhold dose until symptoms resolve and management with corticosteroids is complete
Izpuščaj stopnje 3 Aplikacijo odmerka zadržite dokler simptomi ne izzvenijo in zdravljenje s kortikosteroidi ni končano.
Grade 3 rash Withhold dose(s) until symptoms resolve and management with corticosteroids is complete
Izpuščaj stopnje 3 Aplikacijo odmerka (odmerkov) zadržite dokler simptomi ne izzvenijo in zdravljenje s kortikosteroidi ni končano.
Grade 3 reactions occurred in 10.7% of lenvatinib-treated patients and none in placebo- treated patients.
Neželeni učinek stopnje 3 se je pojavil pri 10,7 % bolnikov, zdravljenih z lenvatinibom, in pri nobenem od bolnikov, ki so prejemali placebo.
Grade 3 thyroid disorders were reported in 0.1% (2/1728) of patients.
O boleznih ščitnice stopnje 3 so poročali pri 0,1 % (2/1.728) bolnikov.
Grade 3 vomiting as  6 episodes in 24 hours over pretreatment; or need for intravenous fluids.
Bruhanje 3. stopnje je definirano z  6 dogodki v 24 urah po predzdravljenju ali s potrebo po intravenskem dodajanju tekočin.
Grade 3*
topnja 3
Grade 3-
Toksičnost stopnje
Grade 3-4
Stopnja 3-4
Grade 3-4
Stopnji 3-4
Grade 3-4 (%)
3.-4. stopnje (%)
Grade 3-4 ADRs with an incidence of ≥5% were liver laboratory test abnormalities, fatigue, diarrhoea, nausea and hyperglycaemia.
Neželeni učinki stopnje 3-4 s pogostnostjo ≥5 % so bili patološki izvidi laboratorijskih jetrnih testov, utrujenost, diareja, navzea in hiperglikemija.
Grade 3-4 ATE occurred in 1.7% of patients treated with ZALTRAP and 1.0% of patients treated with placebo (see section 4.4).
ATE 3. do 4. stopnje so se pojavile pri 1,7 % prejemnikov zdravila ZALTRAP in pri 1,0 % prejemnikov placeba (glejte poglavje 4.4).
Grade 3-4 compromised wound healing occurred in 0.2% of patients treated with ZALTRAP and none of patients treated with placebo (see section 4.4).
Slabše celjenje ran 3. do 4. stopnje se je pojavilo pri 0,2 % prejemnikov zdravila ZALTRAP in pri nobenem prejemniku placeba (glejte poglavje 4.4).
Grade 3-4 dehydration was reported in 4.3% of patients treated with the ZALTRAP/FOLFIRI regimen compared to 1.3% of patients treated with the placebo/FOLFIRI regimen (see section 4.4).
Dehidracijo 3. do 4. stopnje so zabeležili pri 4,3 % prejemnikov sheme ZALTRAP/FOLFIRI in pri 1,3 % prejemnikov sheme placebo/FOLFIRI (glejte poglavje 4.4).
Grade 3-4 diarrhoea was reported in 19.3% of patients treated with the ZALTRAP/FOLFIRI regimen compared to 7.8% of patients treated with the placebo/FOLFIRI regimen.
Drisko 3. do 4. stopnje so zabeležili pri 19,3 % prejemnikov sheme ZALTRAP/FOLFIRI in pri 7,8 % prejemnikov sheme placebo/FOLFIRI.
Grade 3-4 events occurred in 11 patients (1.8%) treated with the ZALTRAP/FOLFIRI regimen and 3 patients (0.5%) treated with the placebo/FOLFIRI regimen.
Dogodki 3. do 4. stopnje so se pojavili pri 11 (1,8 %) prejemnikih sheme ZALTRAP/FOLFIRI in 3 (0,5 %) prejemnikih sheme placebo/FOLFIRI.
Grade 3-4 events were experienced by 1% of patients in each arm.
Učinki stopnje 3 do 4 so se pojavili pri 1 % bolnikov v vsaki skupini.
Grade 3-4 fistula occurred in 0.2% of patients treated with ZALTRAP and 0.1% of patients treated with placebo (see section 4.4).
Fistule 3. do 4. stopnje so se pojavile pri 0,2 % prejemnikov zdravila ZALTRAP in pri 0,1 % prejemnikov placeba (glejte poglavje 4.4).
Grade 3-4 GI perforation events occurred in 0.8% of patients treated with ZALTRAP and 0.2% of patients treated with placebo (see section 4.4).
Perforacija prebavil 3. do 4. stopnje se je pojavila pri 0,8 % prejemnikov zdravila ZALTRAP in pri 0,2 % prejemnikov placeba (glejte poglavje 4.4).
Grade 3-4 GI perforation events occurred in all 3 patients (0.5%) treated with the ZALTRAP/FOLFIRI regimen and in 2 patients (0.3%) treated with the placebo/FOLFIRI regimen.
Perforacija prebavil 3. do 4. stopnje se je pojavila pri 3 (0,5 %) prejemnikih sheme placebo/FOLFIRI in pri 2 (0,3 %) prejemnikih sheme placebo/FOLFIRI.
Grade 3-4 haemorrhage including GI haemorrhage, haematuria, and post-procedural haemorrhage was reported in 2.9% of patients receiving the ZALTRAP/FOLFIRI regimen compared with 1.7% of patients receiving the placebo/FOLFIRI regimen.
Krvavitve 3. do 4. stopnje, vključno s krvavitvami v prebavilih, hematurijo in krvavitvami po posegih, so bile opisane pri 2,9 % prejemnikov sheme ZALTRAP/FOLFIRI in 1,7 % prejemnikov sheme placebo/FOLFIRI.
Grade 3-4 neutropenia was observed in 36.7% of patients treated with the ZALTRAP/FOLFIRI regimen compared to 29.5% patients treated with the placebo/FOLFIRI regimen.
Nevtropenija 3. do 4. stopnje se je pojavila pri 36,7 % prejemnikov sheme ZALTRAP/FOLFIRI in pri 29,5 % prejemnikov sheme placebo/FOLFIRI.
Grade 3-4 neutropenic infection/sepsis occurred in 1.5% of patients treated with the ZALTRAP/FOLFIRI regimen and 1.2% of patients treated with the placebo/FOLFIRI regimen (see section 4.4).
Nevtropenična okužba/sepsa 3. do 4. stopnje se je pojavila pri 1,5 % prejemnikov sheme ZALTRAP/FOLFIRI in pri 1,2 % prejemnikov sheme placebo/FOLFIRI (glejte poglavje 4.4).
Grade 3-4 proteinuria occurred in 7.9% of patients treated with the ZALTRAP/FOLFIRI regimen compared to 1.2% of patients treated with the placebo/FOLFIRI regimen.
Proteinurija 3. do 4. stopnje se je pojavila pri 7,9 % prejemnikov sheme ZALTRAP/FOLFIRI in pri 1,2 % prejemnikov sheme placebo/FOLFIRI.
Grade 3-4 toxicity (%)
Toksičn ost stopenj 3–4 (%)
Grade 3-4 toxicity (%)
Toksičnos t stopnje 3–4 (%)
Grade 3-4 toxicity (%)
Toksičnos t v razredih 3–4 (%)
Grade 3-4 toxicity (%)
Toksičnost stopnje 3-4 (%)
Grade 3-4 toxicity (%)
Toksičnost v razredih 3–4 (%)
Grade 3-4 toxicity (%)
Toksičnost vseh stopenj (%)
Grade 3-4 VTE occurred in 7.9% of patients treated with the ZALTRAP/FOLFIRI regimen and in 6.3% of patients treated with the placebo/FOLFIRI regimen.
VTE 3. do 4. stopnje so se pojavili pri 7,9 % prejemnikov sheme ZALTRAP/FOLFIRI in pri 6,3 % prejemnikov sheme placebo/FOLFIRI.
Grade 3/4 cardiac failure events were reported in 1.0% patients and fatal cardiac failure events were reported in 0.3% patients receiving axitinib.
O dogodkih srčnega popuščanja 3. oziroma 4. stopnje so poročali pri 1,0 % bolnikov, ki so prejemali aksitinib, o dogodkih srčnega popuščanja s smrtnim izidom pa pri 0,3 % bolnikov, ki so prejemali aksitinib.
Grade 3/4 frequency
Pogostnost stopnje 3/4
Grade 3/4 increase in blood CK was reported in 8% of patients taking Odomzo 200 mg.
O zvišanju vrednosti kreatin-kinaze 3. oziroma 4. stopnje so poročali pri 8 % bolnikov, ki so jemali zdravilo Odomzo v odmerku 200 mg.
Grade 3/4 increases in total bilirubin were observed in 5% of patients (all in patients with HIV co- infection who were receiving concomitant atazanavir, with Child-Pugh A, B, or C cirrhosis, or who were post-liver transplant).
O povečanju vrednosti skupnega bilirubina stopnje 3/4 so poročali pri 5 % bolnikov (vsa ta povečanja so bila pri bolnikih s sočasno okužbo z virusom HIV, ki so sočasno prejemali atazanavir, s cirozo Child-Pugh A, B ali C ali po presaditvi jeter).
Grade 3−4 ADRs/Frequency
/ preferenčni izraz
Grade 3−4 ADRs/Frequency
/preferenčni izraz
Grade 3−4 ADRs/Frequency
labirinta
Grade 4
topnja 4
Grade 4 (%)
stopnja 4 (%)
Grade 4 (<0.5x109/l)
Stopnja 4 (<0,5x109/l)
Grade 4 (despite medical management)
topnja 4 (kljub medicinski obravnavi)
Grade 4 (life threatening): Infusion must be stopped and therapy must be permanently discontinued.
4. stopnja (življenje ogrožajoče): Infundiranje je treba ustaviti in zdravljenje trajno končati.
Grade 4 (life-threatening consequences; urgent intervention indicated) and/or severe autonomic neuropathy
Stopnja 4 (posledice, ki ogrožajo življenje;potrebno je nujno ukrepanje ) in/ali huda avtonomna nevropatija
Grade 4 (life-threatening consequences; urgent intervention indicated) and/or severe autonomic neuropathy
Stopnja 4 (posledice, ki ogrožajo življenje;potrebno je nujno ukrepanje ) in/ali močna avtonomna nevropatija
Grade 4 (life-threatening)
Stopnja 4 (življenje ogrožajoča)
Grade 4 (life-threatening): Permanently discontinue DARZALEX treatment.
Reakcija stopnje 4 (življenjsko nevarna): dokončno ukinite zdravilo DARZALEX.
Grade 4 (neuropathy which is disabling)
4. stopnja (nevropatija, ki bolnika onesposobi)
Grade 4 (Platelets:  25,000/mm3)
4. stopnja (trombociti:  25.000/mm3)
Grade 4 ( 10  the ULN)
4. stopnja ( 10  ZNM)
Grade 4 ( 20  the ULN)
4. stopnja ( 20  ZNM)
Grade 4 creatinine elevation Permanently discontinue treatment
Zvišanje vrednosti kreatinina stopnje 4 Zdravljenje trajno ukinite.
Grade 4 cutaneous toxicity, diarrhoea, or mucositis
kožna toksičnost, driska ali mukozitis 4.
Grade 4 diabetes
Diabetes stopnje 4
Grade 4 diarrhoea is an increase of 10 stools/day or grossly bloody diarrhoea or the need for parenteral support.
Driska stopnje 4 pomeni 10 ali več izpraznitev črevesa na dan ali močne krvave driske ali potrebo po parenteralni hidraciji.
Grade 4 diarrhoea or colitis Permanently discontinue treatment
Driska ali kolitis stopnje 4 Zdravljenje trajno ukinite.
Grade 4 febrile neutropenia episodes were observed infrequently (0.6% in lenalidomide/dexamethasone-treated patients compared to 0.0% in placebo/dexamethasone treated patients; see section 4.8).
Epizod febrilne nevtropenije 4. stopnje niso opazili pogosto (0,6% pri bolnikih, ki so prejemali lenalidomid/deksametazon, v primerjavi z 0,0% pri bolnikih, ki so prejemali placebo/deksametazon; glejte poglavje 4.8).
Grade 4 febrile neutropenia episodes were observed infrequently (1.7% in MPR+R/MPR+p treated patients compared to 0.0 % in MPp+p treated patients; see section 4.8).
Epizode febrilne nevtropenije 4, stopnje so opazili redko (1,7 % bolnikov, zdravljenih z MPR+R/MPR+p v primerjavi z 0,0 % bolnikov, zdravljenih z MPp+p; glejte poglavje 4.8).
Grade 4 febrile neutropenia episodes were observed infrequently (1.7% in MPR+R/MPR+p treated patients compared to 0.0 % in MPp+p treated patients; see section 4.8).
Epizode febrilne nevtropenije stopnje 4 so opazili redko (1,7 % bolnikov, zdravljenih z MPR+R/MPR+p v primerjavi z 0,0 % bolnikov, zdravljenih z MPp+p; glejte poglavje 4.8).
Grade 4 febrile neutropenia was observed infrequently (0.6% compared with 0.7% in MPT).
Febrilno nevtropenijo 4. stopnje so redko opazili (0,6 % v primerjavi z 0,7 % pri MPT).
Grade 4 haemorrhagic adverse reactions were reported in 1% of patients and fatal haemorrhage were reported in 0.4% of patients receiving axitinib.
4. stopnje so poročali pri 1 % bolnikov, o krvavitvi s smrtnim izidom pa pri 0,4 % bolnikov, ki so prejemali aksitinib.
Grade 4 hypertension (hypertensive crisis) was reported in 1 patient (0.2%) treated with the ZALTRAP/FOLFIRI regimen.
Hipertenzija 4. stopnje (hipertenzivna kriza) je bila opisana pri 1 prejemniku (0,2 %) sheme ZALTRAP/FOLFIRI.
Grade 4 hypothyroidism
Hipotiroidizem stopnje 4
Grade 4 n (%)
4 (0,5)
Grade 4 n (%)
4. stopnja n (%)
Grade 4 n (%)
stopnja 4 št. (%)
Grade 4 neutropenia was observed in the lenalidomide arms in combination with low dose dexamethasone to a lesser extent than in the comparator arm (8.5% in the Rd [continuous treatment] and Rd18 [treatment for 18 four-week cycles] compared with 15% in the melphalan/prednisone/thalidomide arm, see section 4.8).
Nevtropenijo 4. stopnje so opazili v skupinah z lenalidomidom v kombinaciji z deksametazonom v majhnem odmerku v manjši meri kot v skupini s primerjalnim zdravilom (8,5 % v Rd [neprekinjeno zdravljenje] in Rd18 [zdravljenje v 18 štiritedenskih ciklih], v primerjavi s 15 % v skupini z melfalanom, prednizonom in talidomidom, glejte poglavje 4.8).
Grade 4 QTc prolongation
podaljšanje intervala QTc stopnje 4
Grade 4 rash or Grade 3 pruritus
kožni izpuščaj stopnje 4 ali srbenje stopnje 3
Grade 4 rash Permanently discontinue treatment
Izpuščaj stopnje 4 Zdravljenje trajno ukinite.
Grade 4 thrombocytopenia the docetaxel dose should be reduced from 75 to 60 mg/m2.
2 trombocitopenije 4. stopnje je treba odmerek docetaksela zmanjšati s 75 na 60 mg/m .
Grade 4(life-threatening) - < 120 mmol/L despite appropriate fluid management
Stopnja 4 (življenje ogrožajoča) – < 120 mmol/l kljub primernemu upravljanju tekočin
Grade 4*
stopnja 4
Grade 4*
topnja 4
Grade > 3
topnja > 3
Grade of hepatic impairment*
Stopnja jetrne okvare
grade ≤1, then reinitiate with dose reduced by one decrement.
topnje ≤1, nato zdravljenje nadaljujte z odmerkom, ki je za eno stopnjo nižji od predhodnega.
Grade ≥ 3 (%)
Stopnja ≥ 3 (%)
Grade ≥ 3 (%)
Stopnje ≥3 (%)
Grade ≥ 3 non-haematological toxicities considered to be related to Bortezomib Hospira
Ne-hematološka toksičnost stopnje ≥ 3 povezana z uporabo zdravila Bortezomib Hospira
Grade ≥ 3 peripheral neuropathy occurred in 6% of patients in the subcutaneous treatment group, compared with 16% in the intravenous treatment group (p=0.0264).
Periferna nevropatija  3. stopnje se je pojavila pri 6% bolnikov v skupini s subkutanim dajanjem v primerjavi s 16% bolnikov v skupini, ki je prejemala bortezomib intravensko (p=0,0264).
Grade ≥ 3 venous thromboembolic events were reported in 3.0% of patients in the Kd arm and 1.5% of patients in the Vd arm.
O venskih tromboemboličnih dogodkih ≥ 3 stopnje so poročali pri 3,0 % bolnikov v skupini Kd in 1,5 % bolnikov v skupini Vd.
Grade ≥3 events occurring in 4% of patients in the Cotellic plus vemurafenib arm vs 0% in the placebo plus vemurafenib arm.
Dogodki stopnje ≥ 3 so se pojavili pri 4 % bolnikov v skupini z zdravilom Cotellic in vemurafenibom ter pri 0 % v skupini s placebom in vemurafenibom.
Grade*
Stopnja* Ukrepanje
Grade1 (includes grade
1. stopnja (vključuje
Grade1 (includes grade
Histološka stopnja
Grade3 and 4 neutropenia was seen in 7.5% and 2.7% of patients, respectively, and grade3 thrombocytopenia in 0.7% of patients.
Nevtropenijo 3. in 4. stopnje so odkrili pri 7,5 % oziroma 2,7 % bolnikov, trombocitopenijo 3. stopnje pa pri 0,7 % bolnikov.
Grade>3 n (%)
>3. stopnje n (%)
Grades 1 and 2
Stopnji 1 in 2
Grades 1-4 (%)
1.-4. stopnje (%)
Grades 3 and 4 thrombocytopaenia and/or neutropaenia have been observed in the MCL clinical trial (see section 4.8).
Trombocitopenijo in/ali nevtropenijo 3. in 4. stopnje so opazili v kliničnem preskušanju MCL (glejte poglavje 4.8).
Grades 3 and 4*
3. in 4. stopnja
Grades 3-4
Stopnja 3-4
Grades 3-4a (%)
stopnji 3-4a (%)
Grades 3/4** n=318 ( 5%)
3. ali 4. stopnje** n=318 ( 5% )
Gradual escalation from 10 to 30 mg
postopno povečevanje od 10 do 30 mg
Gradual escalation from 3 to 10 to 30 mg
postopno povečevanje od 3 do 10 do 30 mg
graduation)
na po
Graft complication, Graft delamination,
zapleti z vsadkom,
Graft delamination (complete or partial, possibly leading to loose bodies in the joint or graft failure)
imptomatska hipertrofija presadka, razslojitev presadka (popolna ali delna, kar lahko povzroči prosta telesa v sklepu ali neuspeh presadka).
Graft delamination Graft complication Graft hypertrophy
razslojitev presadka zapleti s presadkom hipertrofija presadka
Graft delamination:
Razslojitev presadka:
graft dysfunction
motnje delovanja presadka
Graft hypertrophy:
Hipertrofija presadka:
Graft infection, Staphylococcal infection
Okužba presadka, stafilokokna okužba
Graft Loss (%)
Izguba presadka (%)
Graft loss Cartilage injury
izguba presadka poškodba hrustanca
Graft thrombosis
Tromboza presadka
Graft versus Host Disease (GvHD) has also been reported (see below).
Poročali so tudi o reakcijah presadka proti gostitelju (GvHD) (glejte nadaljevanje).
Graft versus Host Disease (GvHD) has also been reported (see section c below).
Poročali so o bolezni presadka proti prejemniku (GvHD) (glejte poglavje c spodaj).
Graft versus Host Disease (GvHD) has also been reported.
Poročali so tudi o bolezni presadka proti gostitelju (GvHD - Graft versus Host Disease).
Graft versus Host Diseaseb
reakcija presadka proti gostiteljub
Graft versus Host Diseaseb
reakcije presadka proti gostiteljub
Graft- versus-host disease occurred in 10 patients who were then given ganciclovir or valganciclovir, either alone or in combination with other medicines.
Reakcija presadka proti gostitelju se je pojavila pri 10 bolnikih, ki so nato prejeli ganciklovir ali valganciklovir, samega ali v kombinaciji z drugimi zdravili.
Gram negative anaerobes: S ≤ 1mg/L and R > 1 mg/L
Gram negativni anaerobi: S ≤ 1 mg/l in R > 1 mg/l
Gram negative organisms
po Gramu negativni organizmi
Gram-negative
gramnegativnimi
Gram-negative Aerobes Acinetobacter baumannii Burkholderia cepacia Enterobacter aerogenes Enterobacter cloacae* Klebsiella pneumoniae* Morganella morganii Proteus spp.
Gramnegativni aerobi Acinetobacter baumannii Burkholderia cepacia Enterobacter aerogenes Enterobacter cloacae* Klebsiella pneumoniae* Morganella morganii Proteus spp.
Gram-negative aerobes Citrobacter diversus Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae* Haemophilus influenzae* Escherichia coli* Klebsiella pneumoniae* Klebsiella oxytoca Morganella morganii Proteus mirabilis* Proteus vulgaris Providencia rettgeri Providencia stuartii Salmonella spp.
Gram-negativni aerobi Citrobacter diversus Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae* Haemophilus influenzae* Escherichia coli* Klebsiella pneumoniae* Klebsiella oxytoca Morganella morganii Proteus mirabilis* Proteus vulgaris Providencia rettgeri Providencia stuartii Salmonella spp.
Gram-negative Aerobes Citrobacter freundii* Citrobacter koseri Escherichia coli* Klebsiella oxytoca*
Gramnegativni aerobi Citrobacter freundii* Citrobacter koseri Escherichia coli* Klebsiella oxytoca
Gram-negative aerobes Stenotrophomonas maltophilia Legionella spp.
Gram-negativni aerobi Stenotrophomonas maltophila Legionella spp.
Gram-negative bacteria Enterobacter cloacae Escherichia coli Klebsiella oxytoca
Gramnegativne bakterije Enterobacter cloacae Escherichia coli
Gram-negative bacteria Escherichia coli Klebsiella pneumoniae Proteus mirabilis
Gramnegativne bakterije Escherichia coli Klebsiella pneumoniae Proteus mirabilis
Gram-positive Aerobes Enterococcus spp.† Staphylococcus aureus* Staphylococcus epidermidis Staphylococcus haemolyticus Streptococcus agalactiae*
Grampozitivni aerobi Enterococcus spp.† Staphylococcus aureus* Staphylococcus epidermidis Staphylococcus haemolyticus Streptococcus agalactiae
Grand mal convulsion Serotonin syndrome Speech disorder
generalizirana konvulzija serotoninski sindrom motnje govora
Grange road Dublin 13 Ireland
Grange road Dublin 13 Irska
Granisetron has been shown to block both sodium and potassium channels, which could affect cardiac depolorisation and repolarisation and therefore PR, QRS, and QT intervals.
Pokazali so, da granisetron blokira tako natrijeve kot kalijeve kanalčke, kar bi lahko vplivalo na depolarizacijo in repolarizacijo srca in s tem na intervale PR, QRS in QT.
Granisetron is mainly metabolised to 7-hydroxygranisetron and 9’N-desmethylgranisetron.
Granisetron se v glavnem presnavlja v 7-hidroksigranisetron in 9’N-desmetilgranisetron.
Granisetron may be affected by direct natural or artificial sunlight.
Direktna naravna ali umetna sončna svetloba lahko vpliva na granisetron.
Granule in sachet 56 sachets
zrnca v vrečici 56 vrečic
Granule in sachet Contains 14 sachets
zrnca v vrečici Vsebuje 14 vrečic.
Granule in sachet Contains 14 sachets
Škatla vsebuje: 4 posamezne zloženke s po 14 vrečic na zloženko.
Granule Recovery: Eli Lilly and Company, Lilly Technology Center Building 130, Indianapolis, Indiana, USA
Ponovna granulacija: Eli Lilly and Company, Lilly Technology Center Building 130, Indianapolis, Indiana, ZDA
Granules
Stična
Granules
zrnca
Granules are added to the water and stirred.
Zrnca se ob mešanju stresejo v vodo.
Granules for oral
Zrnca za peroralno
Granules for oral suspension
Zrnca za peroralno raztopino
Granules for oral suspension 30 sachets
Zrnca za peroralno suspenzijo 30 vrečic
Granules for oral suspension should be given to the patient within 30 minutes of mixing.
Zrnca za peroralno suspenzijo morate bolniku dati v 30 minutah po mešanju.
Granules for oral suspension should be given to your child within 30 minutes of mixing.
Zrnca za peroralno suspenzijo morate otroku dati v 30 minutah po mešanju z vodo.
Granules for oral suspension Yellow granules
zrnca za peroralno suspenzijo rumena zrnca
Granules for use in drinking water
Zrnca za uporabo v vodi za pitje.
Granules for use in drinking water for chickens and turkeys - 40 g sachet
Zrnca za uporabo v vodi za pitje za piščance in purane (40 g vrečka)
Granules for use in drinking water for chickens and turkeys - 400 g sachet
Zrnca za uporabo v vodi za pitje za piščance in purane (400 g vrečka)
Granules for use in drinking water for pheasants - 40 g sachet
Zrnca za dajanje v vodo za pitje za fazane– 40 g vrečka
Granules for use in drinking water for pheasants - 400 g sachet
Zrnca za uporabo v vodi za pitje za fazane (400 g vrečka)
Granules for use in drinking water for pigs – 160 g sachet
Zrnca za dajanje v vodo za pitje za prašiče – 160 g vrečka
Granules for use in drinking water for pigs – 40 g sachet
Zrnca za dajanje v vodo za pitje za prašiče – 40 g vrečka
Granules for use in drinking water for pigs – 400 g sachet
Zrnca za dajanje v vodo za pitje za prašiče – 400 g vrečka
Granules for use in drinking water.
Zrnca za dajanje v vodo za pitje.